Adverse effects of immunoglobulin therapy.

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Vnitrni lekarstvi

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 30909703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update on the use of immunoglobulin in human disease: A review of evidence

  2017cited by this paper
• Intravenous and subcutaneous immunoglobulin G replacement therapy.

  2016influential reference
• Managing patients with side effects and adverse events to immunoglobulin therapy

  2016cited by this paper
• No evidence of asymptomatic variant CJD infection in immunodeficiency patients treated with UK‐sourced immunoglobulin

  2016cited by this paper
• Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study

  2015cited by this paper
• Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

  2015cited by this paper
• Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.

  2014cited by this paper
• Adverse effects of IgG therapy.

  2013cited by this paper
• Adverse effects of human immunoglobulin therapy.

  2013influential reference
• Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases

  2012cited by this paper
• Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients

  2012cited by this paper
• The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature.

  2012cited by this paper
• History of immunoglobulin replacement.

  2008cited by this paper
• Intravenous immunoglobulin: adverse reactions and management.

  2008cited by this paper
• Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes.

  2008cited by this paper
• Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency

  2008cited by this paper
• Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.

  2008cited by this paper
• Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.

  2008cited by this paper
• Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action

  2007cited by this paper
• Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency

  2007cited by this paper
• Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route.

  2007cited by this paper
• Safety of IGIV therapy and infusion-related adverse events

  2007influential reference
• Safety of intravenous immunoglobulin (IVIG) therapy.

  2007cited by this paper
• A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions

  2006cited by this paper
• Critical Decisions in Selecting an Intravenous Immunoglobulin Product

  2005cited by this paper
• IgG Anti-IgA Subclasses in Common Variable Immunodeficiency and Association with Severe Adverse Reactions to Intravenous Immunoglobulin Therapy

  2004cited by this paper
• IVIG – mechanisms of action

  2003cited by this paper
• Prospective audit of adverse reactions occurring in 459 primary antibody‐deficient patients receiving intravenous immunoglobulin

  2003cited by this paper
• [Intravenous immunoglobulin (Endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children].

  2003cited by this paper
• Risks associated with the use of intravenous immunoglobulin.

  2003cited by this paper
• European surveillance of immunoglobulin safety--results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries.

  2002cited by this paper
• Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations

  2000cited by this paper
• Adverse Effects of Intravenous Immunoglobulin Therapy

  1999cited by this paper
• Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.

  1999cited by this paper
• Induction of unresponsiveness against IgA in IgA‐deficient patients on subcutaneous immunoglobulin infusion therapy

  1998cited by this paper
• Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status.

  1997cited by this paper
• Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study.

  1996cited by this paper
• Side-effects of intravenous immune globulins.

  1994cited by this paper
• Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.

  1994cited by this paper
• Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors

  1994cited by this paper
• Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies

  1993cited by this paper
• Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.

  1991cited by this paper
• Follow-up of anti-IgA antibodies in primary immunodeficient patients treated with gamma-globulin.

  1989cited by this paper
• Administration of immune globulin associated with aseptic meningitis.

  1988cited by this paper
• Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.

  1986cited by this paper
• Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin

  1983cited by this paper
• High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

  1981cited by this paper
• Gammaglobulin treatment and anti-IgA antibodies in IgA-deficient patients.

  1978cited by this paper
• Intravenous administration of human gamma-globulin.

  1962cited by this paper

• Current and Upcoming Treatment Modalities in Myasthenia Gravis

  2021cites this paper
• Reconsidering anaphylaxis at the time of COVID-19 pandemic.

  2020cites this paper